Back to Agenda
Session 3: Artificial Intelligence Panel: Regulatory Affairs in the Age of Artificial Intelligence
Session Chair(s)
Jake Doran
Managing Director, List Innovations, United States
Karen McCarthy Schau
Sr. Director, Clinical Sciences and Data Integrity, Vertex Pharmaceuticals, United States
Thomas Noto
Senior Director, Regulatory Operations, Lexicon Pharmaceuticals, United States
In this panel discussion, we will explore how the Regulatory function is positioned in the age of Artificial Intelligence and emerging technologies. From exploring whether it is hype or reality, to evaluating potential use cases, to building business cases, and evaluating organizational readiness for a change of this magnitude; this session will bring together industry leaders to share insight into how Artificial Intelligence will impact Regulatory. As more and more use cases are defined and practical implementation is realized, how will we see the application and impact play out over the next few years?
Learning Objective :
At the conclusion of this session, participants should be able to:
- Understand various use cases for Artificial Intelligence across Regulatory
- Understand the challenges and obstacles organizations face when embarking on exploratory initiatives, such as AI
- Learn about the impact a regulated environment and health authorities will have on adoption of this technology
Speaker(s)
Panelist
Global Life Sciences Solutions Lead, Clarivate Analytics, United States
Panelist
Drug Development Multi-Functionalist, LifeSciHub , United States
Panelist
Executive Director, Global Regulatory Operations Strategy & Innovation, BeOne Medicines USA, Inc., United States
Panelist
Global Compliance, Healthcare and Life Sciences, Amazon Web Services (AWS), United States
Panelist
Senior Director, Global Regulatory Operations, Incyte, United States
Panelist
Managing Partner, Gens & Associates, United States
Have an account?